155 related articles for article (PubMed ID: 18534705)
21. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.
Duncan R; Kopecková P; Strohalm J; Hume IC; Lloyd JB; Kopecek J
Br J Cancer; 1988 Feb; 57(2):147-56. PubMed ID: 3358905
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
Ríhová B; Etrych T; Pechar M; Jelínková M; Stastný M; Hovorka O; Kovár M; Ulbrich K
J Control Release; 2001 Jul; 74(1-3):225-32. PubMed ID: 11489498
[TBL] [Abstract][Full Text] [Related]
23. Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.
Sadzuka Y; Sugiyama T; Suzuki H; Sawanishi H; Miyamoto K
Toxicol Lett; 2004 May; 150(3):341-9. PubMed ID: 15110086
[TBL] [Abstract][Full Text] [Related]
24. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice.
Seymour LW; Ulbrich K; Wedge SR; Hume IC; Strohalm J; Duncan R
Br J Cancer; 1991 Jun; 63(6):859-66. PubMed ID: 1648946
[TBL] [Abstract][Full Text] [Related]
25. Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.
Zhang L; Zhang R; Yang J; Wang J; Kopeček J
J Control Release; 2016 Aug; 235():306-318. PubMed ID: 27266365
[TBL] [Abstract][Full Text] [Related]
26. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers.
Wang D; Kopecková JP; Minko T; Nanayakkara V; Kopecek J
Biomacromolecules; 2000; 1(3):313-9. PubMed ID: 11710118
[TBL] [Abstract][Full Text] [Related]
28. Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):375-83. PubMed ID: 8866656
[TBL] [Abstract][Full Text] [Related]
29. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
Duncan R; Gac-Breton S; Keane R; Musila R; Sat YN; Satchi R; Searle F
J Control Release; 2001 Jul; 74(1-3):135-46. PubMed ID: 11489490
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice.
Peterson CM; Lu JM; Sun Y; Peterson CA; Shiah JG; Straight RC; Kopecek J
Cancer Res; 1996 Sep; 56(17):3980-5. PubMed ID: 8752167
[TBL] [Abstract][Full Text] [Related]
32. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
33. Polymer conjugated bovine seminal ribonuclease inhibits growth of solid tumors and development of metastases in mice.
Soucek J; Poucková P; Zadinová M; Hlousková D; Plocová D; Strohalm J; Hrkal Z; Oleár T; Ulbrich K
Neoplasma; 2001; 48(2):127-32. PubMed ID: 11478693
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates.
Shiah JG; Sun Y; Kopecková P; Peterson CM; Straight RC; Kopecek J
J Control Release; 2001 Jul; 74(1-3):249-53. PubMed ID: 11489502
[TBL] [Abstract][Full Text] [Related]
35. HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation.
Zarabi B; Nan A; Zhuo J; Gullapalli R; Ghandehari H
Macromol Biosci; 2008 Aug; 8(8):741-8. PubMed ID: 18484565
[TBL] [Abstract][Full Text] [Related]
36. Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug.
Zunino F; Pratesi G; Pezzoni G
Cancer Treat Rep; 1987 Apr; 71(4):367-73. PubMed ID: 3829013
[TBL] [Abstract][Full Text] [Related]
37. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system.
Yokoyama M; Okano T; Sakurai Y; Fukushima S; Okamoto K; Kataoka K
J Drug Target; 1999; 7(3):171-86. PubMed ID: 10680973
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
[TBL] [Abstract][Full Text] [Related]
39. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.
Ríhová B; Strohalm J; Prausová J; Kubácková K; Jelínková M; Rozprimová L; Sírová M; Plocová D; Etrych T; Subr V; Mrkvan T; Kovár M; Ulbrich K
J Control Release; 2003 Aug; 91(1-2):1-16. PubMed ID: 12932633
[TBL] [Abstract][Full Text] [Related]
40. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
